Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study

Table 1 Clinical inputs considered in the model

	Value of the parameter
	Ranolazine (%)	SoC (%)
Transition probabilities
Adherence to treatment with ranolazine [23]	0.720
Angina frequency [22]
Minimum	0.040	0.000
Mild	0.605	0.071
Moderate	0.208	0.689
Severe	0.137	0.241
Hospitalization [25]
With minimum angina frequency	0.200	0.200
With mild angina frequency	0.200	0.200
With moderate angina frequency	0.270	0.270
With severe angina frequency	0.300	0.300
Revascularization [26]
Revascularization	0.500	0.500
Revascularization with CABG	0.280	0.280
Revascularization with PTCA	0.720	0.720
Utility values [27]
No hospitalization, minimum angina frequency	0.810	0.840
No hospitalization, mild angina frequency	0.750	0.750
No hospitalization, moderate angina frequency	0.600	0.600
No hospitalization, severe angina frequency	0.390	0.390
Hospitalization without revascularization, minimum angina frequency	0.800	0.800
Hospitalization without revascularization, mild angina frequency	0.740	0.740
Hospitalization without revascularization, moderate angina frequency	0.590	0.590
Hospitalization without revascularization, severe angina frequency	0.380	0.380
Revascularization, minimum angina frequency	0.750	0.750
Revascularization, mild angina frequency	0.690	0.690
Revascularization, moderate angina frequency	0.540	0.540
Revascularization, severe angina frequency	0.330	0.330

CABG: coronary artery bypass graft, PCI/STENT: percutaneous transluminal angioplasty & stenting, SoC: standard of care

ISSN: 1472-6963